X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MP0533 is a T-cell engager, leveraging the cell surface protein CD3 as a powerful immune activator, complemented by novel control mechanisms designed to help direct CD3-mediated cytotoxicity with heightened precision. It is being studied for AML.
Lead Product(s): MP0533
Therapeutic Area: Oncology Product Name: MP0533
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
MP0310 is a dual-targeted compound, targeting both FAP and 4-1BB, that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming to avoid systemic side effects associated with 4-1BB activation.
Lead Product(s): MP0310
Therapeutic Area: Oncology Product Name: MP0310
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
MP0420 (ensovibep) is a COVID-19 antiviral therapeutic candidate designed specifically to inactivate SARS-CoV-2 – the virus that causes COVID-19 – with extremely high potency that is preserved against novel variants.
Lead Product(s): Ensovibep
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2022
Details:
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of MP0420/SKO136 (ensovibep), a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction.
Lead Product(s): Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
Laboratory studies using full Omicron pseudovirus confirm MP0420 (ensovibep), maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs.
Lead Product(s): Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
Details:
In vitro data to-date demonstrate that ensovibep retains potency in inhibiting all known SARS-CoV-2 variants of concern, including the Delta variants. Ensovibep is the lead therapeutic candidate in Molecular Partners’ infectious disease pipeline.
Lead Product(s): Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
In the results presented, neutralization assays demonstrate ensovibep’s ability to potently neutralize SARS-CoV-2 when testing the Wuhan or a reference strain.
Lead Product(s): Ensovibep
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Details:
The collaboration will combine Molecular Partners’ industry-leading ability to rapidly generate high-affinity DARPins and the RLT capabilities and expertise of Novartis. DARPins have great potential to enable robust, tumor-specific delivery of radioligands.
Lead Product(s): DARPin-conjugated Radioligand Therapies
Therapeutic Area: Oncology Product Name: DARPin-RLTs
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $580.0 million Upfront Cash: $20.0 million
Deal Type: Acquisition October 14, 2021
Details:
Abicipar is a long-acting anti-VEGF DARPin® molecule which was invented by Molecular Partners and initially licensed to Allergan in 2011.
Lead Product(s): Abicipar Pegol
Therapeutic Area: Ophthalmology Product Name: AGN-150998
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 09, 2021
Details:
MP0420 is a clinical-stage candidate that is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ infectious disease program.
Lead Product(s): Ensovibep
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $63.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
